TriSalus Life Sciences (TLSI) News Today → Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad) Free TLSI Stock Alerts $7.44 -0.06 (-0.80%) (As of 05/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 9:18 AM | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Receives New Coverage from Analysts at Canaccord Genuity GroupCanaccord Genuity Group began coverage on TriSalus Life Sciences in a research report on Thursday. They set a "buy" rating and a $12.00 price target on the stock.May 30 at 8:22 AM | americanbankingnews.comTriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Canaccord Genuity GroupMay 24, 2024 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to WarrantsMay 16, 2024 | seekingalpha.comTLSI TriSalus Life Sciences, Inc.May 16, 2024 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comTLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024May 15, 2024 | businesswire.comTriSalus Reports Q1 2024 Financial Results and Business UpdateMay 11, 2024 | msn.comJonesTrading Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy RecommendationMay 10, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Receives New Coverage from Analysts at JonestradingJonestrading started coverage on shares of TriSalus Life Sciences in a research note on Friday. They set a "buy" rating and a $16.00 price target on the stock.May 7, 2024 | businesswire.comTriSalus Life Sciences Appoints Liselotte Hyveled to its Board of DirectorsMay 6, 2024 | businesswire.comTriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference CallApril 30, 2024 | businesswire.comTriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth InitiativesApril 5, 2024 | morningstar.comTriSalus Life Sciences IncApril 3, 2024 | benzinga.comTriSalus Life Sciences Stock (NASDAQ:TLSI), Earnings Estimates, EPS, and RevenueApril 2, 2024 | insidermonkey.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2023 Earnings Call TranscriptApril 1, 2024 | markets.businessinsider.comTriSalus Life Sciences, Inc. Q4 sales increaseApril 1, 2024 | finance.yahoo.comTriSalus Reports Q4 and Full Year 2023 Financial Results and Business UpdateApril 1, 2024 | finance.yahoo.comTriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ...March 26, 2024 | finance.yahoo.comTriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific MeetingMarch 21, 2024 | finance.yahoo.comTriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific MeetingMarch 11, 2024 | businesswire.comTriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for "Nelitolimod" as the Nonproprietary Drug Name for SD-101March 7, 2024 | businesswire.comTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101February 29, 2024 | businesswire.comTriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver TumorsJanuary 24, 2024 | seekingalpha.comTriSalus Life Sciences: Rocket-Like Recovery Could Be An Inflection PointJanuary 9, 2024 | morningstar.comTriSalus Life Sciences Inc TLSIDecember 17, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)December 15, 2023 | msn.comTriSalus Life Sciences files to sell 5.9 million shares for holdersDecember 15, 2023 | msn.comMyomo, Aileron Therapeutics among healthcare moversDecember 13, 2023 | finance.yahoo.comTriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023December 11, 2023 | marketbeat.comTrading was temporarily halted for "TLSI" at 12:12 PM with a stated reason of "LULD pause."August 18, 2023 | marketbeat.comTrading was temporarily halted for "TLSI" at 09:08 AM with a stated reason of "LULD pause."August 11, 2023 | marketbeat.comTrading was temporarily halted for "TLSI" at 11:08 AM with a stated reason of "LULD pause." Trading set to resume at 11:08 AM. August 11, 2023 | marketbeat.comTrading was temporarily halted for "TLSI" at 10:08 AM with a stated reason of "LULD pause."August 11, 2023 | marketbeat.comTrading was temporarily halted for "TLSI" at 10:08 AM with a stated reason of "LULD pause."August 11, 2023 | marketbeat.comTrading was temporarily halted for "TLSI" at 09:08 AM with a stated reason of "LULD pause."August 11, 2023 | marketbeat.comTrading was temporarily halted for "TLSI" at 09:08 AM with a stated reason of "LULD pause." Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s Final Masterpiece: “X-9840” (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. TLSI Media Mentions By Week TLSI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSI News Sentiment▼1.250.80▲Average Medical News Sentiment TLSI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSI Articles This Week▼70▲TLSI Articles Average Week Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sight Sciences News Today Nyxoah News Today Inovio Pharmaceuticals News Today Utah Medical Products News Today AngioDynamics News Today NeuroPace News Today Tactile Systems Technology News Today Treace Medical Concepts News Today Delcath Systems News Today AVITA Medical News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSI) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarElon Musk’s Final Masterpiece: “X-9840”Paradigm PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaThe only financial event in 2024 that matters Porter & CompanyMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
